NCCN Guideline Updates

NCCN Updated Guideline Adds Treatment Options for HER2-Positive Breast Cancer, Emphasizing CDK4/CDK6 Inhibition in Hormone-Sensitive Disease

Wayne Kuznar

July 2018, Vol 8, No 7 - NCCN Guideline Updates

An updated guideline from the National Comprehensive Cancer Network (NCCN) on the management of breast cancer (version 1.2018) expands treatment options for hormone receptor (HR)-positive, HER2-positive disease to include extended adjuvant neratinib (Nerlynx) treatment after trastuzumab (Herceptin) therapy in patients at high risk for recurrence, and recognizes a third cyclin-dependent kinase (CDK)4/CDK6 inhibitor in hormone-sensitive breast cancer. [ Read More ]

Updated NCCN Guidelines Expand Targeted Therapy Options for Patients with Metastatic NSCLC

Wayne Kuznar

July 2018, Vol 8, No 7 - NCCN Guideline Updates

Updated guidelines from the National Comprehensive Cancer Network (NCCN) on the management of patients with metastatic non–small-cell lung cancer (NSCLC) reflect the addition of osimertinib (Tagrisso) as a first-line treatment option for patients with an EGFR-sensitizing mutation, and as subsequent therapy for patients with a T790M resistance mutation whose disease progresses after treatment with another tyrosine kinase inhibitor (TKI). [ Read More ]

NCCN Issues First Guideline for Immunotherapy-Related Adverse Events

Wayne Kuznar

May 2018, Vol 8, No 5 - NCCN Guideline Updates

The National Comprehensive Cancer Network (NCCN)’s first guideline (version 1.2018) for the management of side effects from immunotherapy recognizes “a new spectrum of adverse events” in patients who are receiving immune checkpoint inhibitor therapy, said John A. Thompson, MD, Director, Phase I Clinical Trials Program, Fred Hutchinson Cancer Research Center, Seattle, WA, at the 2018 NCCN annual conference. Dr Thompson is also chair of the NCCN panel on the management of immunotherapy-related toxicity. [ Read More ]

Updated NCCN Prostate Cancer Guideline Emphasizes Risk Stratification

Wayne Kuznar

May 2018, Vol 8, No 5 - NCCN Guideline Updates

The updated prostate cancer guideline issued by the National Comprehensive Cancer Network (NCCN) continues to support early detection efforts in well-informed, healthy men, but acknowledges that the optimal screening of high-risk patients is not completely known. The guideline also supports the use of active surveillance in men who have low-risk prostate cancer. [ Read More ]